

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	International Application No.: PCT/EP99/08038
Ruelle	:	I.A. Filing Date: 03 May 1999
Serial No.: 09/674,779	:	Priority Date: 06 May 1998
For: BASB019 Proteins and Genes From	:	
Moraxella Catarrhalis, Antigens,	:	
Antibodies and Uses	:	

Commissioner for Patents  
Box PCT  
Washington, D.C. 20231  
Attn.: Lamont Hunter  
National Stage Processing

COMMUNICATION REGARDING MISSING PRIORITY DATE


Sir:

The priority date of "06 May 1998" was erroneously omitted on the communication entitled "Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office" dated 15 December 2000 as noted on the enclosed copy.

The subject application was filed as a National stage application of International Application No. PCT/EP99/03038, filed 03 May 1999 which claims priority of Application No. GB 9809683.7, filed 06 May 1998. The priority date is clearly identified on the first page of the International application as published which accompanied the "National Stage Application Transmittal Letter" when submitted with the US Receiving Office on November 6, 2000 by the attorney for the applicant, copy also enclosed. Thus, the subject application is entitled to claim the priority date of "06 May 1998".

Accordingly, applicant requests the priority date of "06 May 1998" be made of record in the subject application.

Respectfully submitted,

  
Arthur E. Jackson  
Registration No. 34,354  
Attorney for Applicant


DECHERT  
4000 Bell Atlantic Tower  
1717 Arch Street  
Philadelphia, PA 19103-2793  
Fax: (609) 620-3259  
Attn: Arthur E. Jackson, Esq.  
(609) 620-3254

Docket No. BM45311  
Serial No. 09/674,779

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper and the documents referred to as being transmitted therewith are being deposited with the United States Postal Service on this date January 3, 2001 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EK 295 393 950 US addressed to: Commissioner for Patents, Box PCT, Washington, D.C. 20231, Attn.: Lamont Hunter, National Stage Processing.

Colleen Hanagan

  
Signature of person mailing paper

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/31, 15/62, C07K 14/21, 16/12, A61K 39/02, 39/40, G01N 33/50</b>		A2	(11) International Publication Number: <b>WO 99/57277</b>
			(43) International Publication Date: 11 November 1999 (11.11.99)
(21) International Application Number: <b>PCT/EP99/03038</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>3 May 1999 (03.05.99)</b>		<p>Published</p> <p>Without international search report and to be republished upon receipt of that report.</p>	
(30) Priority Data: <b>9809683.7 6 May 1998 (06.05.98) GB</b>			
(71) Applicant (for all designated States except US): <b>SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).</b>			
(72) Inventor; and (75) Inventor/Applicant (for US only): <b>RUELLE, Jean-Louis [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).</b>			
(74) Agent: <b>TYRRELL, Arthur, William, Russell; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</b>			

(54) Title: **BASB019 PROTEINS AND GENES FROM MORAXELLA CATARRHALIS, ANTIGENS, ANTIBODIES, AND USES**

(57) Abstract

The invention provides BASB019 polypeptides and polynucleotides encoding BASB019 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

Coomasie stained SDS-PAGE of BASB019 protein

